This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Xuanzhu Biopharmaceutical Co., Ltd.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Wenkui Ken Fang: Innovator in Pharmaceutical Advancements
Introduction
Wenkui Ken Fang is a prominent inventor based in Shandong, China, renowned for his contributions to the field of pharmaceuticals. With a single patent to his name, he is making strides in the development of innovative therapeutics aimed at addressing FXR-mediated diseases. Fang's work not only embodies a commitment to advancing medical science but also highlights the intersection of innovation and healthcare.
Latest Patents
Wenkui Ken Fang holds a patent for an FXR agonist, categorized within the technical realm of pharmaceuticals. The invention relates to a compound represented by a specific formula, including its pharmaceutically acceptable salts, esters, and stereoisomers. Furthermore, Fang's patent delineates a comprehensive preparation method for these compounds and details their applications in pharmaceutical formulations. This discovery holds significant implications for the treatment and prevention of diseases mediated by FXR, showcasing Fang's ability to merge scientific knowledge with practical applications.
Career Highlights
Fang's career is marked by his association with Xuanzhu Biopharmaceutical Co., Ltd., where he has dedicated his expertise to advancing pharmaceutical research and innovation. His deep understanding of drug development processes and his focus on therapeutic efficacy have positioned him as a key player in the industry. Despite having a limited number of patents, his work reflects a strong foundation in medication design and technological advancement.
Collaborations
Throughout his career, Wenkui Ken Fang has collaborated with talented colleagues, including Bo Chen and Tingzhong Wang. These partnerships emphasize the importance of teamwork in the innovation process, enabling the fusion of diverse ideas and expertise to drive forward-thinking solutions in the biotech space. Together, they strive to create groundbreaking therapies that can benefit patients worldwide.
Conclusion
Wenkui Ken Fang represents the spirit of innovation within the pharmaceutical industry, with his work on FXR agonists contributing to new possibilities for treating complex diseases. As he continues to work with Xuanzhu Biopharmaceutical Co., Ltd., and collaborate with other experts, his future endeavors could pave the way for new medical breakthroughs, ultimately improving patient outcomes and enhancing global health.